Lyra Therapeutics reports FY2023 net loss $62.7M; ENLIGHTEN I Phase 3 topline expected Q2 2024

Lyra Therapeutics, Inc.

Net loss $62.7M in FY2023 ($15.1M Q4); R&D $48.0M, G&A $19.1M; cash $102.8M, runway into Q1 2025.
Topline results from ENLIGHTEN I Phase 3 trial of LYR-210 in CRS anticipated Q2 2024.
ENLIGHTEN II enrollment completion expected H2 2024; ENLIGHTEN I 52-week extension results Q4 2024.
BEACON Phase 2 of LYR-220 met safety endpoint; significant SNOT-22 (−16.8; p=0.007) and 3CS (−1.50; p=0.02) improvement vs sham at week 24.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Lyra Therapeutics, Inc. reported financial results for the fourth quarter and full year ended December 31, 2023.

Period: the fourth quarter and full year ended December 31, 2023
Result: reported results

Exact text from the filing

announced its financial results for the year ended December 31, 2023.

View on SEC.gov

20 earnings releases filed in the last 30 days. Browse all earnings releases →

Lyra Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-034701

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.